Insulet (PODD) on Friday announced it had established a new contract with UnitedHealthcare (UNH), which would provide its patients with in-network, durable medical equipment coverage for Omnipod beginning April 1, William Blair analyst Margaret Kaczor tells investors in a research note. This is another coverage win for Insulet as UnitedHealth represents almost 50M lives in the United States, the analyst adds. She notes Insulet has had limited access to historically a Medtronic (MDT) has been UnitedHealth's preferred, in-network DME insulin pump provider since mid-2016. Kaczor views the announcement as "another improvement in patient access to Omnipod." She thinks Insulet "continues to fire on all cylinders" and keeps an Outperform rating on the shares.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Biohaven Pharmaceutical... To see the rest of the story go to thefly.com. See Story Here

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here